Prognostic and therapeutic implications of Apc mutation in colorectal cancer

Surgeon

Volumn 6, Issue 6, 2008, Pages 350-356

  Quyn, A J ^a,b   Steele, R J C ^b   Carey, F A ^b   Nathke I S ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adenomatous polyposis coli; Colorectal cancer

Indexed keywords

EID: 58049216512     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(08)80007-8     Document Type: Review

References (87)

1. Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. BMJ 2000;321(7264):805-8
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumourigenesis. Cell 1990;61(5):759-67
3. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002;89(7):845-60
4. Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002;38(7):867-71
5. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256(5057):668-70
6. Brittan M, Wright NA. Gastrointestinal stem cells. J Pathol 2002;197(4):492-509
7. Marshman E, Booth C, Potten CS. The intestinal epithelial stem cell. Bioessays 2002;24(1):91-98
8. Potten CS, Owen G, Booth D. Intestinal stem cells protect their genome by selective segregation of template DNA strands. J Cell Sci 2002;115 (Pt 11):2381-88
9. Leedham S, Wright N. Expansion of a mutated clone from stem cell to tumour. J Clin Pathol 2007
10. Nathke IS. The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol 2004;20:337-66
11. Dikovskaya D, Schiffmann D, Newton IP, et al. Loss of APC induces polyploidy as a result of a combination of defects in mitosis and apoptosis. J Cell Biol 2007;176(2):183-95
12. Bienz M. The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol 2002;3(5):328-38
13. Brantjes H, Barker N, van Es J, Clevers H. TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol Chem 2002;383(2):255-61
14. Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci 2002;115(Pt 21):3977-78
15. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003;94(3):225-29
16. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002;296(5573):1644-46
17. van Noort M, Clevers H. TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev Biol 2002;244(1):1-8
18. Kroboth K, Newton IP, Kita K, et al. Lack of adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in microtubule stability. Mol Biol Cell 2007;18(3):910-18
19. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004;18(12):1385-90
20. Green RA, Kaplan KB. Chromosome instability in colorectal tumour cells is associated with defects in microtubule plus-end attachments caused by a dominant mutation in APC. J Cell Biol 2003;163(5):949-61
21. Weinberg R. The biology of cancer: Garland Science, 2007.
22. Nugent KP, Phillips RK, Hodgson SV, et al. Pheno-typic expression in familial adenomatous polyposis: partial prediction by mutation analysis. Gut 1994;35(11):1622-23
23. Rozen P, Samuel Z, Shomrat R, Legum C. Notable intrafamilial phenotypic variability in a kindred with familial adenomatous polyposis and an APC mutation in exon 9. Gut 1999;45(6):829-33
24. Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993;75(5):951-57
25. Nagase H, Miyoshi Y, Horii A, et al. Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 1992;52(14):4055-57
26. Eccles DM, Lunt PW, Wallis Y, et al. An unusually severe phenotype for familial adenomatous polyposis. Arch Dis Child 1997;77(5):431-35
27. Caspari R, Friedl W, Mandl M, et al. Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. Lancet 1994;343(8898):629-32
28. Gayther SA, Wells D, SenGupta SB, et al. Regionally clustered APC mutations are associated with a severe phenotype and occur at a high frequency in new mutation cases of adenomatous polyposis coli. Hum Mol Genet 1994;3(1):53-56
29. Dobbie Z, Spycher M, Hurliman R, et al. Mutational analysis of the first 14 exons of the adenomatous polyposis coli (APC) gene. Eur J Cancer 1994;30A(11):1709-13
30. Wallis YL, Macdonald F, Hulten M, et al. Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. Hum Genet 1994;94(5):543-48
31. Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998;62(6):1290-301
32. Friedl W, Meuschel S, Caspari R, et al. Attenuated familial adenomatous polyposis due to a mutation in the 3′ part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet 1996;97(5):579-84
33. van der Luijt RB, Vasen HF, Tops CM, Breukel C, Fodde R, Meera Khan P. APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet 1995;96(6):705-10
34. Young J, Simms LA, Tarish J, et al. A family with attenuated familial adenomatous polyposis due to a mutation in the alternatively spliced region of APC exon 9. Hum Mutat 1998;11(6):450-55
35. Sieber OM, Segditsas S, Knudsen AL, et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut 2006;55(10):1440-48
36. van der Luijt RB, Meera Khan P, Vasen HF, et al. Germline mutations in the 3′ part of APC exon 15 do not result in truncated proteins and are associated with attenuated adenomatous polyposis coli. Hum Genet 1996;98(6):727-34
37. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005;54(9):1283-86
38. Hsieh JS, Lin SR, Chang MY, et al. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and post-operative surveillance. Am Surg 2005;71(4):336-43
39. Deuter R, Linz J, Pietsch S, Winde G, Hentsch S, Muller O. DNA alterations in sporadic colorectal tumors do not correlate with tumor staging diagnosed by the TNM system. Cancer Lett 1996;109 (1-2):161-69
40. De Filippo C, Luceri C, Caderni G, et al. Mutations of the APC gene in human sporadic colorectal cancers. Scand J Gastroenterol 2002;37(9):1048-53
41. Luchtenborg M, Weijenberg MP, Roemen GM, et al. APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis 2004;25(7):1219-26
42. Dihlmann S, von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005;113(4):515-24
43. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997;1332(3):F127-47
44. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004;31(2 Suppl 7):12-21
45. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005;310(5753):1504-10
46. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90(21):1609-20.
47. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90(20):1529-36
48. Marx J. Cancer research. Anti-inflammatories inhibit cancer growth-but how? Science 2001;291(5504):581-82
49. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998;95(2):681-6.
50. Chan TA. Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. Curr Cancer Drug Targets 2003;3(6):455-63
51. Stark LA, Din FV, Zwacka RM, Dunlop MG. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. Faseb J 2001;15(7):1273-75
52. Husain SS, Szabo IL, Tamawski AS. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002;97(3):542-53
53. Wick M, Hurteau G, Dessev C, et al. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002;62(5):1207-14
54. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325(23):1593-96
55. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121(4):241-46
56. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333(10):609-14
57. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/ TCF-4 signaling. Oncogene 2001;20(5):645-53
58. Germann MW, Aramini JM, Kalisch BW, van de Sande JH. Structural, dynamic, and enzymatic properties of mixed alpha/beta-oligonucleotides containing polarity reversals. Nucleosides Nucleoticles Nucleic Acids 2001;20(4-7):493-39
59. Smith ML, Hawcroft G, Hull MA. The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000;36(5):664-74
60. Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 2002;23(1):107-14
61. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157(1):175-79
62. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328(18):1313-16
63. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101(3):635-39
64. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993;88(10):1652-56
65. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108(4):1083-7.
66. Graham TA, Ferkey DM, Mao F, Kimelman D, Xu W. Tcf4 can specifically recognize beta-catenin using alternative conformations. Nat Struct Biol 2001;8(12):1048-52
67. Graham TA, Weaver C, Mao F, Kimelman D, Xu W. Crystal structure of a beta-catenin/Tcf complex. Cell 2000;103(6):885-96
68. Poy F, Lepourcelet M, Shivdasani RA, Eck MJ. Structure of a human Tcf4-beta-catenin complex. Nat Struct Biol 2001;8(12):1053-57
69. Molenaar M, van de Wetering M, Oosterwegel M, et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996;86(3):391-99
70. Su Y, Ishikawa S, Kojima M, Liu B. Eradication of pathogenic beta-catenin by Skp1/Cullin/F box ubiquitination machinery. Proc Natl Acad Sci U S A 2003;100 (22):12729-34
71. Cong F, Zhang J, Pao W, Zhou P, Varmus H. A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol 2003;4:10
72. Liu J, Stevens J, Matsunami N, White RL. Targeted degradation of beta-catenin by chimeric F-box fusion proteins. Biochem Biophys Res Commun 2004;313(4):1023-29
73. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001;8(4):308-15
74. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19(2):289-98
75. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60(22):6359-66
76. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9(2):555-61
77. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/ refractory epithelial ovarian cancer. J Clin Oncol 2002;20(6):1562-69
78. Brunori M, Malerba M, Kashiwazaki H, Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virol 2001;75(6):2857-65
79. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000;81(Pt 11):2573-604
80. Cornelis JJ, Spruyt N, Spegelaere P, et al. Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression. J Virol 1988;62(9):3438-44
81. Cornelis JJ, Becquart P, Duponchel N, et al. Transformation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibility to the autonomous parvoviruses H-1 virus and minute virus of mice. J Virol 1988;62(5):1679-86
82. Dupressoir T, Vanacker JM, Cornelis JJ, Duponchel N, Rommelaere J. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 1989;49(12):3203-8.
83. Van Pachterbeke C, Tuynder M, Cosyn JP, Lespagnard L, Larsimont D, Rommelaere J. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer 1993;55(4):672-77
84. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9(4):1291-300
85. Sansom OJ, Meniel VS, Muncan V, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007;446 (7136):676-79
86. Tan AR, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol 2003;30 (5 Suppl 16):54-64
87. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-37